roquinimex and Glomerulonephritis

Autoimmune MRL/1 mice were treated with a recently developed substance with immunomodulating properties, LS-2616. Treatment was initiated at the age of 8 weeks, before the onset of clinically apparent disease, and at 16 weeks of age, after development of established lupus disease. Beneficial therapeutic effects were obtained, even when LS-2616 was administered at the lowest dose tested (1 mg/mouse/week) to 16-week-old mice. The effects of LS-2616 on longevity, as well as on development of lymphadenopathy, splenomegaly, glomerulonephritis, and vasculitis, were pronounced and were comparable with those of cyclophosphamide. The results obtained suggest a potential role for LS-2616 in the treatment of autoimmune disease in humans.

Topics: Adjuvants, Immunologic; Animals; Autoimmune Diseases; Cyclophosphamide; Drug Evaluation, Preclinical; Female; Glomerulonephritis; Hydroxyquinolines; Immunity; Lymphatic Diseases; Mice; Mice, Inbred Strains; Splenomegaly; Vasculitis